---
source_url: https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/hiv_infection
content_type: therapeutic_choices
document_id: hiv_infection
source_system: CPS (Canadian Pharmacists Association)
processed_at: '2025-05-29T07:19:41.056827Z'
processing_stage: url_preservation_final
pipeline_version: '1.0'
download_date: unknown
converted_from: hiv_infection.html
redownload_instructions:
  method: Use unified downloader
  command: python cps_unified_downloader.py --types therapeutic_choices
  note: Requires valid CPS access credentials
---

# HIV Infection: Treatment

### HIV Infection: Treatment

|  |
| --- |
| Marianne Harris, MD, CCFPChristine Hughes, BScPharm, PharmD |
| Date of Revision: April 24, 2023 |
| Peer Review Date: October 8, 2022 |


#### Introduction

Human immunodeficiency virus (HIV) is a chronic viral infection that, left untreated, ultimately leads to death from opportunistic infections and/or specific cancers associated with acquired immunodeficiency syndrome (AIDS). However, since the advent and availability of highly active combination antiretroviral therapy (cART) in the mid-1990s, the prognosis has shifted dramatically.‚Äã[^[1]]‚Äã[^[2]]‚Äã[^[3]] The primary goal of therapy, to preserve the health of the individual living with HIV, is readily achievable with current cART, and in most cases HIV can be considered a chronic manageable condition. The benefits of cART are maximized when it is given continuously, starting as early as possible in the course of HIV infection, to avert damage to the immune system and irreversible organ damage caused by chronic inflammation.‚Äã[^[4]]‚Äã[^[5]]‚Äã[^[6]]‚Äã[^[7]]

In addition, widespread use of cART has significant benefits at the population level by preventing new HIV infections.‚Äã[^[8]]‚Äã[^[9]]‚Äã[^[10]] In conjunction with education and other prevention strategies, expanded use of cART in the ‚Äútreatment as prevention‚Äù model has the potential to significantly impact the HIV epidemic. Early diagnosis is critical to achieving the proven benefits of early HIV treatment at both the individual and societal levels. This highlights the need to expand HIV testing and incorporate it as part of standard health care for all sexually active adults. This chapter discusses treatment of adult patients with chronic HIV infection as diagnosed by a positive HIV antibody/antigen test; for information related to screening patients who do not have an established diagnosis of HIV infection, see HIV Infection: Prevention.

#### Goals of Therapy



#### Investigations



#### Therapeutic Choices

#### Nonpharmacologic Choices

Management recommendations for patients with HIV infection are included in Table 1.

| CD4 count (cells/mcL) | Action |
| --- | --- |
| At all levels | General counselling (risk of onward transmission and practices to prevent transmission, legal implications of HIV nondisclosure with their sexual partner, proper nutrition, physical activity, need for follow-up, importance of adherence)History and physical examination at least annuallyAs soon as patient is ready, start antiretroviral therapy; early initiation of antiretroviral therapy is associated with significantly improved survival‚Äã[15]‚Äã[16]‚Äã[17]Plasma viral load every 3‚Äì4 months; can be decreased to every 6 months if on stable antiretroviral therapy with viral load <40 copies/mL and good adherence for >1 y; increase monitoring if symptomatic or diagnosed with AIDS-defining illnessCD4 count every 3‚Äì4 months; CD4 monitoring is optional if viral load <40 copies/mL and CD4 >250 cells/mcL for >1 y; increase monitoring if symptomatic or diagnosed with AIDSPneumococcal vaccine (per local guidelines and availability); hepatitis A and B vaccines if appropriate based on serology; update diphtheria, tetanus and pertussis (Td/TdaP) vaccines as needed; annual influenza vaccination; if required, measles/mumps/rubella (MMR) and varicella vaccines if CD4 >200 cells/mcL and not pregnant; meningococcal vaccine every 5 y; HPV, herpes zoster, and COVID-19 vaccines (per current local guidelines); Mpox vaccine (if available and appropriate).TST and/or IGRA; treatment of latent tuberculosis infection if indicated (see Tuberculosis) |
| <200 | Start prophylaxis for PJP if not starting antiretroviral therapy imminently (see HIV Infection: Opportunistic Infections) |
| <100 | Start toxoplasmosis prophylaxis if seropositive and not on sulfamethoxazole/trimethoprim for PJP prophylaxis (see HIV Infection: Opportunistic Infections) |


acquired immunodeficiency syndrome

coronavirus disease 2019

human immunodeficiency virus

human papillomavirus

Interferon gamma release assay

Pneumocystis jirovecii pneumonia

tuberculin skin test

#### Pharmacologic Choices

#### Antiretroviral Therapy

#### General approach to antiretroviral therapy

Combination antiretroviral therapy (cART) is recommended in all individuals living with HIV with detectable HIV viremia. Irrespective of CD4 count, HIV infection confers an increased risk for non-AIDS-associated cancers, coronary artery disease, hepatic and renal disease, and other conditions, possibly due to uncontrolled viral replication and chronic immune activation.‚Äã[^[6]]‚Äã[^[7]]

Durability of the treatment effect is related to the prevention of drug resistance and this is achieved only with consistent suppression of viral replication. Long-term nonprogression of the disease can be expected if the plasma viral load is maintained below the level of detection on a long-term basis; however, the clinical significance of a viral load result between 40 and 200 copies/mL is uncertain.‚Äã[^[13]]‚Äã[^[14]] Therefore, the goal of plasma viral load suppression is HIV RNA <40 copies/mL (for polymerase chain reaction assays), whereas the inability to maintain levels <200 copies/mL is considered virologic failure.‚Äã[^[13]]‚Äã[^[14]] 

Effective control of HIV infection with cART reduces the incidence of opportunistic infections and certain cancers and prolongs life.‚Äã[^[1]]‚Äã[^[2]]‚Äã[^[3]] It also decreases infectivity and lowers the risk of HIV transmission from pregnant patients to their infants, between drug-using partners and among sexual contacts.‚Äã[^[9]]‚Äã[^[18]]‚Äã[^[19]] A systematic review by the Public Health Agency of Canada demonstrated a negligible risk of sexual transmission of HIV from an HIV-positive partner who is adherent to antiretroviral therapy and who has a consistently suppressed viral load (<200 copies/mL).‚Äã[^[20]]

Early initiation of antiretroviral therapy is associated with significantly improved survival.‚Äã[^[5]] Initiation of antiretroviral therapy should be considered more urgently in symptomatic patients; those with a history of an AIDS-defining illness; those with HIV-associated nephropathy, hepatitis B or C co-infection or newly diagnosed malignancy; those with HIV-uninfected sexual partners; and in pregnant patients.‚Äã[^[13]]‚Äã[^[14]]

Long-term treatment with certain cART may be associated with metabolic complications and reduced bone mineral density; however, these effects are offset by the demonstrated improvement in survival and significantly reduced rates of major cardiovascular, hepatic and renal events associated with continuous antiretroviral therapy.‚Äã[^[7]]‚Äã[^[21]]‚Äã[^[22]]

#### Recommended cART regimens

**Combination antiretroviral therapy** (cART) is the standard of care for initial therapy and is defined as a combination of at least 3 active antiretroviral drugs or, in specific cases, 2 antiretroviral drugs.‚Äã[^[13]]‚Äã[^[14]] The cART regimens recommended for first-line therapy consist of 2 **nucleoside (or nucleotide) reverse transcriptase inhibitors** (N[t]RTIs) plus either:



| Regimen | Regimen Examples | N[t]RTIs: First and Second Drug | Plus Third (¬± Fourth) Drug | Or (Single-Tablet) Triple Therapy |
| --- | --- | --- | --- | --- |
| 2 N[t]RTIs plus1 Integrase Inhibitor | Abacavir‚Äã[a] (Ziagen, generics) plus lamivudine (3TC, generics)‚Äã[b]Tenofovir DF (Viread, generics) plus lamivudine (3TC, generics)Fixed-dose combinations:Abacavir‚Äã[a]/lamivudine (Kivexa, generics)‚Äã[b]Emtricitabine/tenofovir AF (Descovy)‚Äã[b]‚Äã[c]Emtricitabine/tenofovir DF (Truvada, generics)‚Äã[b] | Dolutegravir (Tivicay)‚Äã[b]Raltegravir (Isentress)‚Äã[b] | Bictegravir/emtricitabine/tenofovir AF (Biktarvy)‚Äã[b]‚Äã[c]Dolutegravir/abacavir‚Äã[a]/lamivudine (Triumeq)‚Äã[b]Elvitegravir/cobicistat/emtricitabine/tenofovir AF (Genvoya)Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Stribild) |  |
| 2 N[t]RTIs plus1 Protease Inhibitor (plus cobicistat or low-dose ritonavir) | Atazanavir (Reyataz, generics) plus low-dose ritonavir (Norvir)Darunavir (Prezista) plus low-dose ritonavir (Norvir)Darunavir/cobicistat (Prezcobix) | Darunavir/cobicistat/emtricitabine/tenofovir AF (Symtuza) |  |  |
| 2 N[t]RTIs plus1 NNRTI | Doravirine (Pifeltro)Efavirenz (Sustiva, generics) Rilpivirine (Edurant)‚Äã[d] | Doravirine/lamivudine/tenofovir DF (Delstrigo) Efavirenz/emtricitabine/tenofovir DF (generics)Emtricitabine/rilpivirine‚Äã[d]/tenofovir AF (Odefsey)Emtricitabine/rilpivirine‚Äã[d]/tenofovir DF (Complera) |  |  |
| 1 NRTI plus1 Integrase Inhibitor | Dolutegravir/lamivudine (Dovato): indicated as first-line therapy in certain individuals‚Äã[b]‚Äã[e] |  |  |  |


non-nucleoside reverse transcriptase inhibitor

nucleoside [or nucleotide] reverse transcriptase inhibitor

tenofovir alafenamide

tenofovir disoproxil fumarate

#### Considerations affecting choice of cART regimen

When selecting the antiretroviral regimen, consider individual patient characteristics (e.g., pretreatment HIV RNA level and CD4 count, HIV genotypic drug resistance test results, HLA-B*5701 status), presence of comorbidities (e.g., renal disease, cardiovascular disease), pregnancy or potential for pregnancy, and regimen-specific considerations (e.g., adverse effects, drug-drug interactions, drug coverage, pill burden and dosing frequency) (see Table 3). Nonadherence to therapy promotes the emergence of drug-resistant HIV strains and is the most important remaining challenge in the management of HIV infection.‚Äã[^[23]]‚Äã[^[24]] Counselling and support are critical to ensure ongoing adherence.‚Äã[^[24]]

Drug interactions are an important consideration whenever starting or stopping antiretrovirals or other drugs.‚Äã[^[13]]‚Äã[^[14]] In addition to toxicity, reduced serum drug levels can be an important consequence. Suboptimal antiretroviral levels not only reduce efficacy but may also promote resistance. All PIs and NNRTIs are metabolized by the CYP450 enzyme system and consequently are associated with many drug interactions. Unboosted integrase inhibitors have fewer clinically significant drug interactions; however, GI absorption can be impaired in the presence of polyvalent cations (e.g., aluminum, calcium, iron, magnesium), potentially resulting in subtherapeutic plasma levels of the integrase inhibitor. N[t]RTIs are not metabolized by CYP450 but other interactions can occur.

If a patient experiences unmanageable drug toxicity, simultaneous cessation of *all* antiretroviral medications is recommended prior to starting a new cART regimen. Avoid decreasing the dosage or stopping only 1 or 2 medications, as this can promote the development of resistance.‚Äã[^[13]]‚Äã[^[14]]‚Äã[^[25]]

In the past, planned treatment interruptions (‚Äúdrug holidays‚Äù) were proposed as a strategy to reduce long-term toxicity and treatment cost for patients; however, the risk of opportunistic infections and death was higher in patients randomized to episodic treatment interruptions based on CD4 count as compared with continuous cART in the SMART study.‚Äã[^[7]] For this reason, treatment interruptions are not recommended.‚Äã[^[13]]‚Äã[^[14]]

A confirmed rebound in plasma viral load implies treatment failure or nonadherence. If adherence is confirmed, drug resistance testing should be performed and the cART regimen should be selected based on the patient‚Äôs antiretroviral therapy history and previous drug resistance results.‚Äã[^[13]]‚Äã[^[14]]

#### Pre- and Post-Exposure Prophylaxis

For a discussion regarding pre- and post-exposure prophylaxis, see HIV Infection: Prevention.

#### Choices during Pregnancy and Breastfeeding

#### HIV Infection and Pregnancy

Optimal management of HIV in pregnancy requires consultation with a physician with expertise in this area. Prepregnancy considerations are beyond the scope of this chapter; for more information, see the Canadian HIV Pregnancy Planning Guidelines.

Considerations during pregnancy should include optimal therapy of the pregnant patient, results of resistance testing, risk of perinatal transmission of HIV, changes in pharmacokinetics of antiretrovirals during pregnancy, and possible teratogenic and other effects of cART on the developing fetus.‚Äã[^[26]] All pregnant patients should be offered cART with a discussion of its risks and benefits.‚Äã[^[13]]‚Äã[^[14]]

#### Choices during Pregnancy

A cART regimen in pregnancy should be designed based on the results of drug resistance testing and should preferably include 2 **N[t]RTIs** and either a ritonavir**-boosted PI** or an unboosted **integrase inhibitor**.‚Äã[^[26]] Two-drug regimens are not recommended during pregnancy.

Preferred N[t]RTIs include abacavir/‚Äãlamivudine (coformulated) (if the gestational parent‚Äôs HLA-B*5701 test is negative), emtricitabine/‚Äãtenofovir DF (coformulated), lamivudine plus tenofovir DF, or emtricitabine/‚Äãtenofovir AF (coformulated). Tenofovir DF should be used with caution in patients with renal insufficiency. Twice-daily coformulated lamivudine/‚Äãzidovudine is an alternative NRTI in pregnancy.

The preferred ritonavir-boosted PI in pregnancy is twice daily darunavir**/**ritonavir. Cobicistat results in insufficient PI drug levels during the second and third trimesters and thus should not be used as a pharmacokinetic booster during pregnancy.

The preferred integrase inhibitor in pregnancy is dolutegravir. Dolutegravir is dosed once daily, rapidly decreases viral load, is well tolerated and associated with fewer drug interactions than boosted PIs.‚Äã[^[26]] Raltegravir is dosed twice daily in pregnancy and is an alternative integrase inhibitor. In a large study in Botswana, dolutegravir use around the time of conception was associated with a slightly higher risk of fetal neural tube defects (0.3% with dolutegravir vs. 0.1% with other antiretrovirals).‚Äã[^[27]] However, updated data from the same study have shown rates of neural tube defects that are not significantly different from those with nondolutegravir regimens.‚Äã[^[28]] Dolutegravir can be considered before and during pregnancy after discussing potential risks and benefits with the patient and ensuring adequate folic acid supplementation.‚Äã[^[26]]‚Äã[^[29]]‚Äã[^[30]]

Elvitegravir/cobicistat is not recommended for initial use in pregnancy due to low elvitegravir drug levels. Injectable cabotegravir is also not recommended due to its long half-life and lack of safety data in pregnancy. There are insufficient data to recommend the use of bictegravir in pregnancy.

Use of other antiretroviral agents should be considered on an individual basis, in consultation with an expert in the management of HIV during pregnancy.

#### Choices during Breastfeeding

Breastfeeding by patients living with HIV is not recommended in Canada due to the risk of HIV transmission to the child (risk <1% but not zero) and readily available infant formulas. Therefore, HIV treatment recommendations for the breastfeeding parent are the same as for the general population of patients living with HIV.

A discussion of general principles on the use of medications in these special populations can be found in Drugs Use during Pregnancy and Drug Use during Breastfeeding. Other specialized reference sources are also provided in these appendices.

#### Therapeutic Tips



#### Drug Table


**Drug Class: Integrase Inhibitors**


**Drug Class: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)**


**Drug Class: Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)**


**Drug Class: Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)**


**Drug Class: Protease Inhibitors (PIs)**


**Drug Class: Entry Inhibitors**


**Drug Class: Combination Antiretrovirals‚Äã[e]**

| Drug/‚ÄãCost[a] | Dosage | Adverse Effects | Drug Interactions[b] | Comments |
| --- | --- | --- | --- | --- |
| **cabotegravir** (Vocabria) | 30 mg (+ rilpivirine 25 mg) once daily PO with food (if taking together with rilpivirine) | Insomnia, headache. | Should be taken 2 h before or 4 h after medications containing polyvalent cations (e.g., aluminum, calcium, iron or magnesium).Pharmacokinetic modelling suggests strong inducers of UGT1A1 and 1A9 (e.g., carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine) may reduce cabotegravir exposure and result in virologic failure. | Not for initial antiviral therapy.Only indicated in combination with oral rilpivirine for patients who are virologically stable with a suppressed viral load (<50 copies/mL) as a short-term lead-in before injectable cabotegravir/rilpivirine or as bridging therapy for missed injections. |
| **dolutegravir** (Tivicay) | 50 mg once daily PO with or without foodIntegrase resistant: 50 mg BID PO | Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable).Weight gain.‚Äã[34]‚Äã[35]Insomnia and other CNS side effects, e.g., headache, fatigue, depression.‚Äã[36]‚Äã[37]‚Äã[38] | Should be taken 2 h before or 6 h after medications containing polyvalent cations (e.g., aluminum, calcium, iron or magnesium) including cation-containing antacids or laxatives, sucralfate, oral iron or calcium supplements, and buffered medications.Dolutegravir significantly increases metformin levels; metformin dose adjustments may be required.‚Äã[39]Numerous potential drug interactions; consult a reputable drug interaction checker or resource. | May be effective against raltegravir- and elvitegravir-resistant virus.Available as dispersible tablets. |
| **raltegravir** (Isentress, Isentress HD) | Regular strength tablet: 400 mg BID PO with or without foodHigh-dose tablet: 1200 mg once daily PO | Rare, severe life-threatening skin and hypersensitivity reactions.Weight gain.‚Äã[34]‚Äã[35]Infrequent neuropsychiatric side effects, e.g., insomnia, depression.‚Äã[40]‚Äã[41]‚Äã[42]Myopathy, myositis, increased CK; rhabdomyolysis (rare).‚Äã[43] | Not an inhibitor or inducer of CYP isozymes. Rifampin decreases raltegravir levels by inducing glucuronidation. Increase raltegravir dose to 800 mg BID when coadministered with rifampin.‚Äã[14]Do not coadminister aluminum- or magnesium-containing antacids and all strengths of raltegravir. Do not coadminister calcium-containing antacids and high dose raltegravir. | Available as chewable tablets. |
| **abacavir** (Ziagen, generics) | 300 mg BID PO or 600 mg once daily PO with or without food | Hypersensitivity reactions in patients with genetic predisposition (HLA-B*5701; can be severe).‚Äã[c]Recent use may be associated with increased risk of myocardial infarction.‚Äã[44] | Abacavir has a low potential for drug interactions. | Screen patients for the presence of HLA-B*5701 before starting; do not use if patient is positive for HLA-B*5701.‚Äã[c]Monitor early on for hypersensitivity reaction.‚Äã[14]Available as an oral solution. |
| **lamivudine (3TC)** (3TC, generics) | 150 mg BID PO or 300 mg once daily PO with or without food | Minimal toxicity, generally well tolerated. | Lamivudine has a low potential for drug interactions. | Avoid in combination with emtricitabine (similar resistance profiles).Available as an oral solution. |
| **zidovudine (AZT)** (Retrovir, generics) | 200 mg TID PO or 300 mg BID PO with or without food | Nausea, headache, malaise, fatigue, rash, myositis, myocarditis, anemia, leukopenia, hepatic steatosis, elevated liver enzymes, lactic acid and CK. Long-term use associated with peripheral lipoatrophy. | Additive hemotoxicity with other agents, e.g., anemia with dapsone, foscarnet, ganciclovir, pentamidine, ribavirin.Numerous potential drug interactions; consult a reputable drug interaction checker or resource. | Avoid in combination with ribavirin.Available as an oral syrup. |
| **tenofovir DF (tenofovir disoproxil fumarate, TDF)** (Viread, generics) | 300 mg once daily PO with or without food | Renal toxicity; monitor renal function, urinalysis and serum phosphorus.Lactic acidosis and hepatotoxicity have been reported.Decreased BMD and increased osteoporotic fractures. | Numerous potential drug interactions; consult a reputable drug interaction checker or resource.Avoid in combination with nephrotoxic drugs. | Dose interval adjustment if ClCr <50 mL/min.Caution is advised in patients with established or at high-risk of osteoporosis (e.g., postmenopausal, chronic systemic corticosteroid therapy). Ensure adequate calcium and vitamin D intake.‚Äã[45]‚Äã[46]TDF decreases atazanavir levels and atazanavir increases TDF levels. |
| **doravirine** (Pifeltro) | 100 mg once daily PO with or without food | GI effects, headache, dizziness, CNS toxicity (e.g., sleep disturbance, abnormal dreams. depressed mood), rash.Rare reports of severe rash, hypersensitivity reactions, immune reconstitution inflammatory syndrome (IRIS). | Numerous potential drug interactions with NNRTIs; consult a reputable drug interaction checker or resource. |  |
| **efavirenz (EFV)** (generics) | 600 mg once daily PO on an empty stomach | CNS toxicity (e.g., sleep disturbance, abnormal dreams, depressed mood), rash, increased liver enzymes, QTc interval prolongation. | Numerous potential drug interactions with NNRTIs; consult a reputable drug interaction checker or resource. | Avoid in patients with a history of anxiety, depression or psychosis.Guidelines list efavirenz as an alternative treatment option in pregnancy.‚Äã[26] However, the product monograph states that it is contraindicated in first trimester of pregnancy. Teratogenicity in nonhuman primates has been reported; however, this has not been demonstrated in humans to date.‚Äã[47] Discuss risks and benefits with patient. |
| **etravirine** (Intelence) | 200 mg BID PO with food | Rash, nausea. Rare reports of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme), hypersensitivity reactions (may include hepatotoxicity or hepatic failure). | Numerous potential drug interactions with NNRTIs; consult a reputable drug interaction checker or resource. | May be effective against NNRTI-resistant HIV. |
| **nevirapine (NVP)** (generics) | 200 mg once daily PO for 2 wk then either: 200 mg BID PO (immediate-release tablet) or400 mg once daily PO (extended-release tablet) with or without food | Rash, severe skin reactions (rare), e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme. Increased liver enzymes (rare cases of fatal hepatitis). | Numerous potential drug interactions with NNRTIs; consult a reputable drug interaction checker or resource. | Not recommended to start NVP if the CD4 count is >250 cells/mcL in women or >400 cells/mcL in men. |
| **rilpivirine (RPV)** (Edurant) | 25 mg once daily PO with food | Depression, insomnia, rash, headache.Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable).QTc interval prolongation. | Numerous potential drug interactions with NNRTIs; consult a reputable drug interaction checker or resource.RPV absorption is acid dependent; stagger administration of antacids (2 h before or 4 h after RPV) or H2-receptor antagonists (12 h before or 4 h after RPV). Use with PPIs is contraindicated. | Use only if HIV RNA levels ‚â§100 000 copies/mL and CD4 count >200 cells/mcL at the time of RPV initiation. |
| **atazanavir** (Reyataz, generics) | Treatment-na√Øve: 400 mg once daily or 300 mg (+ RTV 100 mg) once daily PO with foodTreatment-experienced, pregnant, or with tenofovir DF: 300 mg (+ RTV 100 mg) once daily PO with food | Benign hyperbilirubinemia in patients with a genetic predisposition (MDR1 polymorphism).‚Äã[d]Less common: kidney stones,‚Äã[50]‚Äã[51] possible renal dysfunction,‚Äã[52] gallstones,‚Äã[53] rash.All PIs may be associated with PR and QTc interval prolongation, dyslipidemia and insulin resistance.‚Äã[14]‚Äã[54] | Numerous serious drug interactions exist with PIs; consult a reputable drug interaction checker or resource.Absorption is acid dependent; stagger administration of antacids (administer 2 hours before or 1 hour after antacid) or H2-receptor antagonists (administer simultaneously with, and/or at least 10 hours after H2-receptor antagonist). Use with PPIs is contraindicated. |  |
| **darunavir** (Prezista, generics) | Treatment-na√Øve: 800 mg (+ RTV 100 mg) once daily PO with foodTreatment-experienced (with PI resistance) or pregnant: 600 mg (+ RTV 100 mg) BID PO with food | Diarrhea, nausea, headache, rash (possible cross-sensitivity with sulfonamides).Drug-induced hepatotoxicity, in some cases fatal, has been reported rarely with darunavir in combination with ritonavir.All PIs may be associated with PR and QTc interval prolongation, dyslipidemia and insulin resistance.‚Äã[14]‚Äã[54] | Numerous serious drug interactions exist with PIs; consult a reputable drug interaction checker or resource. | Approved for use only with ritonavir or cobicistat as a boosting agent (do not use darunavir as a sole PI). |
| **darunavir** (Prezcobix) | 800 mg/150 mg once daily PO with food | Diarrhea, nausea, headache, rash (possible cross-sensitivity with sulfonamides).Drug-induced hepatotoxicity, in some cases fatal, has been reported rarely with darunavir in combination with ritonavir.All PIs may be associated with PR and QTc interval prolongation, dyslipidemia and insulin resistance.‚Äã[14]‚Äã[54]Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable). | Numerous serious drug interactions exist with PIs; consult a reputable drug interaction checker or resource. | Cobicistat has no antiviral activity but is a CYP3A inhibitor used to boost darunavir levels. |
| **lopinavir** (Kaletra) | Treatment-na√Øve: 400/100 mg BID PO or 800/200 mg once daily PO with foodTreatment-experienced (with PI resistance) or pregnant: 400/100 mg BID PO with foodWith efavirenz or nevirapine: 400/100 mg, 500/125 mg or 600/150 mg BID PO with food | GI upset, liver enzyme elevations. All PIs may be associated with PR and QTc interval prolongation, dyslipidemia and insulin resistance.‚Äã[14]‚Äã[54]Possible increased risk of renal dysfunction.‚Äã[14]‚Äã[52] | Numerous serious drug interactions exist with PIs; consult a reputable drug interaction checker or resource. | Available as an oral solution. |
| **ritonavir (RTV)** (Norvir) | Used as a PK booster; see atazanavir and darunavir for dosing information | GI upset, diarrhea, circumoral paresthesia, and liver enzyme elevations.All PIs may be associated with PR and QTc interval prolongation, dyslipidemia and insulin resistance.‚Äã[14]‚Äã[54] | Numerous serious drug interactions exist with PIs; consult a reputable drug interaction checker or resource. | As a PK booster, low-dose RTV is a component of many regimens.Avoid use as a sole PI because of adverse effects. |
| **maraviroc** (Celsentri) | 300 mg BID PO, with or without food, with NRTIs, nevirapine and/or other drugs that are not strong inhibitors or inducers of CYP3A4150 mg BID PO with strong CYP3A4 inhibitors including PIs; 600 mg BID PO with strong CYP3A4 inducers including efavirenz, etravirineSee Drug Interactions | Few; generally well-tolerated. | Decreased levels with CYP3A4 inducers: efavirenz, etravirine, rifampin.Increased levels with CYP3A4 inhibitors: PIs, itraconazole, ketoconazole, clarithromycin. | Tropism test required prior to treatment: effective only in patients with CCR5 tropic HIV (not CXCR4 or mixed-tropic virus). |
| **abacavir** (Kivexa, generics) | 600 mg/300 mg once daily PO with or without food | Hypersensitivity reactions in patients with genetic predisposition (HLA-B*5701; can be severe).‚Äã[c] | Abacavir and lamivudine have a low potential for interactions. | Screen patients for the presence of HLA-B*5701 before starting; do not use if patient is positive for HLA-B*5701.‚Äã[c]Renal impairment (ClCr <30 mL/min): not recommended. Use individual products and adjust each agent accordingly. |
| **abacavir** (generics) | 300 mg/150 mg/300 mg BID PO with or without food | Hypersensitivity reactions in patients with genetic predisposition (HLA-B*5701; can be severe).‚Äã[c]Nausea, headache, malaise, fatigue, rash, myositis, myocarditis, anemia, leukopenia, hepatic steatosis, elevated liver enzymes, lactic acid and CK. Long-term use associated with peripheral lipoatrophy. | Abacavir and lamivudine have a low potential for interactions.Additive hemotoxicity with other agents, e.g., anemia with dapsone, foscarnet, ganciclovir, pentamidine, ribavirin.Numerous potential drug interactions; consult a reputable drug interaction checker or resource. | Screen patients for the presence of HLA-B*5701 before starting; do not use if patient is positive for HLA-B*5701.‚Äã[c]Renal impairment (ClCr <30 mL/min): not recommended. Use individual products and adjust each agent accordingly. |
| **bictegravir** (Biktarvy) | 50 mg/200 mg/25 mg once daily PO with or without food | GI upset (nausea, diarrhea); insomnia and other CNS effects, e.g., headache, fatigue. Weight gain.‚Äã[35]Renal toxicity; monitor renal function, urinalysis and serum phosphorus.Lactic acidosis and hepatotoxicity have been reported.Decreased BMD and increased osteoporotic fractures. TAF has potentially less loss of BMD and renal function compared with TDF.‚Äã[55]‚Äã[56] | Should be taken 2 h before or 6 h after medications containing polyvalent cations (e.g., aluminum, calcium, iron or magnesium) including cation-containing antacids or laxatives, sucralfate, oral iron or calcium supplements, and buffered medications.Bictegravir may increase metformin levels; metformin dose adjustments may be required.Numerous potential drug interactions; consult a reputable drug interaction checker or resource. | May be effective against raltegravir- and elvitegravir-resistant virus.Renal impairment (ClCr <30 mL/min): not recommended. For use in patients receiving chronic hemodialysis, refer to product monograph.Bictegravir is not available as a single-entity product. |
| **cabotegravir** (Cabenuva) | Optional oral lead-in (to assess tolerability): cabotegravir 30 mg once daily PO and rilpivirine 25 mg once daily PO √ó 28 days with food, followed by either:Monthly dosing: cabotegravir 600 mg (3 mL) IM plus rilpivirine 900 mg (3 mL) IM √ó 1 dose, then cabotegravir 400 mg (2 mL) plus rilpivirine 600 mg (2 mL) IM monthlyorBimonthly dosing (every 2 months): cabotegravir 600 mg (3 mL) IM plus rilpivirine 900 mg (3 mL) IM monthly√ó 2 doses then every 2 months thereafter | Injection site reactions.Insomnia, headache.Depression, insomnia, rash, headache.Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable).QTc interval prolongation. | No drug interaction studies have been performed with cabotegravir or rilpivirine injection. See drug interaction data for oral cabotegravir and oral rilpivirine, but note that injectable formulations are not affected by food, gastric pH (e.g., antacids, H2-receptor antagonists or PPIs) or polyvalent cations.Theoretical: pharmacokinetic modelling suggests strong inducers of UGT1A1 and 1A9 (e.g., carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine) may reduce cabotegravir exposure and result in virologic failure. | Not for initial antiviral therapy.Only indicated for patients who are virologically stable with a suppressed viral load (<50 copies/mL).If oral lead-in used, final oral doses of cabotegravir and rilpivirine should be taken on the same day that injections are started.Cabotegravir and rilpivirine injections are 2 separate injections given on the same day. |
| **darunavir** (Symtuza) | 800 mg/150 mg/ 200 mg/10 mg once daily PO with food | Diarrhea, nausea, headache, rash (possible cross-sensitivity with sulfonamides).Drug-induced hepatotoxicity, in some cases fatal, has been reported rarely with darunavir in combination with ritonavir.All PIs may be associated with PR and QTc interval prolongation, dyslipidemia and insulin resistance.‚Äã[14]‚Äã[54]Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable). | Numerous serious drug interactions exist with PIs; consult a reputable drug interaction checker or resource.TAF should not be used with rifamycin. | Renal impairment: do not use if pretreatment ClCr <30 mL/min. |
| **dolutegravir** (Dovato) | 50 mg/300 mg once daily PO with or without food | Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable).Weight gain.‚Äã[34]‚Äã[35]Insomnia and other CNS side effects, e.g., headache, fatigue, depression.‚Äã[36]‚Äã[37]‚Äã[38]Minimal toxicity, generally well tolerated. | Should be taken 2 h before or 6 h after medications containing polyvalent cations (e.g., aluminum, calcium, iron or magnesium) including cation-containing antacids or laxatives, sucralfate, oral iron or calcium supplements, and buffered medications.Dolutegravir significantly increases metformin levels; metformin dose adjustments may be required.‚Äã[39]Numerous potential drug interactions; consult a reputable drug interaction checker or resource.Lamivudine has a low potential for drug interactions. | Use as initial therapy only if baseline viral load <500 000 copies/mL.‚Äã[13]‚Äã[14] |
| **dolutegravir** (Juluca) | 50 mg/25 mg once daily PO with food | Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable).Weight gain.‚Äã[34]‚Äã[35]Insomnia and other CNS side effects, e.g., headache, fatigue, depression.‚Äã[36]‚Äã[37]‚Äã[38]Depression, insomnia, rash, headache.Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable).QTc interval prolongation. | Should be taken 2 h before or 6 h after medications containing polyvalent cations (e.g., aluminum, calcium, iron or magnesium) including cation-containing antacids or laxatives, sucralfate, oral iron or calcium supplements, and buffered medications.Dolutegravir significantly increases metformin levels; metformin dose adjustments may be required.‚Äã[39]Numerous potential drug interactions; consult a reputable drug interaction checker or resource.RPV absorption is acid dependent; stagger administration of antacids (2 h before or 4 h after RPV) or H2-receptor antagonists (12 h before or 4 h after RPV). Use with PPIs is contraindicated. | Not for initial antiretroviral therapy; only indicated for patients who are virologically stable with suppressed viral load (<50 copies/mL).Renal impairment: monitor for adverse events if ClCr <30 mL/min. |
| **dolutegravir** (Triumeq) | 50 mg/600 mg/300 mg once daily PO with or without food | Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable).Weight gain.‚Äã[34]‚Äã[35]Insomnia and other CNS side effects, e.g., headache, fatigue, depression.‚Äã[36]‚Äã[37]‚Äã[38]Hypersensitivity reactions in patients with genetic predisposition (HLA-B*5701; can be severe).‚Äã[c] | Should be taken 2 h before or 6 h after medications containing polyvalent cations (e.g., aluminum, calcium, iron or magnesium) including cation-containing antacids or laxatives, sucralfate, oral iron or calcium supplements, and buffered medications.Dolutegravir significantly increases metformin levels; metformin dose adjustments may be required.‚Äã[39]Numerous potential drug interactions; consult a reputable drug interaction checker or resource.Abacavir and lamivudine have a low potential for interactions. | Screen patients for the presence of HLA-B*5701 before starting; do not use if patient is positive for HLA-B*5701.‚Äã[c]May be effective against raltegravir- and elvitegravir-resistant virus.Renal impairment (ClCr <30 mL/min): not recommended. Use individual products and adjust each agent accordingly. |
| **doravirine** (Delstrigo) | 100 mg/300 mg/300 mg once daily PO with or without food | GI effects, headache, dizziness, CNS toxicity (e.g., sleep disturbance, abnormal dreams. depressed mood), rash.Rare reports of severe rash, hypersensitivity reactions, immune reconstitution inflammatory syndrome (IRIS).Renal toxicity; monitor renal function, urinalysis and serum phosphorus.Lactic acidosis and hepatotoxicity have been reported.Decreased BMD and increased osteoporotic fractures. | Numerous potential drug interactions; consult a reputable drug interaction checker or resource.Avoid in combination with nephrotoxic drugs. | Renal impairment (ClCr <50 mL/min): not recommended. Use individual products and adjust each agent accordingly.Caution is advised in patients with established or at high-risk of osteoporosis (e.g., postmenopausal, chronic systemic corticosteroid therapy). Ensure adequate calcium and vitamin D intake.‚Äã[45]‚Äã[46] |
| **efavirenz** (generics) | 600 mg/200 mg/300 mg once daily PO on an empty stomach | CNS toxicity (e.g., sleep disturbance, abnormal dreams, depressed mood), rash, increased liver enzymes, QTc interval prolongation.Renal toxicity; monitor renal function, urinalysis and serum phosphorus.Lactic acidosis and hepatotoxicity have been reported.Decreased BMD and increased osteoporotic fractures. | Numerous potential drug interactions; consult a reputable drug interaction checker or resource.Avoid in combination with nephrotoxic drugs. | Caution is advised in patients with established or at high-risk of osteoporosis (e.g., postmenopausal, chronic systemic corticosteroid therapy). Ensure adequate calcium and vitamin D intake.‚Äã[45]‚Äã[46]Renal impairment (ClCr <50 mL/min): not recommended. Emtricitabine is not available as a single-entity product. |
| **elvitegravir** (Genvoya) | 150 mg/150 mg/200 mg/10 mg once daily PO with food | Diarrhea, headache.Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable).Weight gain.‚Äã[34]‚Äã[35]Renal toxicity; monitor renal function, urinalysis and serum phosphorus.Lactic acidosis and hepatotoxicity have been reported.Decreased BMD and increased osteoporotic fractures. TAF has potentially less loss of BMD and renal function compared with TDF.‚Äã[55]‚Äã[56] | Numerous potential drug interactions; consult a reputable drug interaction checker or resource.Should be separated by at least 2 h from antacids containing aluminum, calcium or magnesium.TAF should not be used with rifamycin. | Cobicistat has no antiviral activity but is a CYP3A inhibitor used to boost elvitegravir levels.Renal impairment: do not use if pretreatment ClCr <30 mL/min. Cobicistat, elvitegravir, emtricitabine and TAF are not available as single-entity products. |
| **elvitegravir** (Stribild) | 150 mg/150 mg/200 mg/300 mg once daily PO with food | Diarrhea, headache.Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable).Renal toxicity; monitor renal function, urinalysis and serum phosphorus.Lactic acidosis and hepatotoxicity have been reported.Decreased BMD and increased osteoporotic fractures. | Numerous potential drug interactions; consult a reputable drug interaction checker or resource.Should be separated by at least 2 h from antacids containing aluminum, calcium or magnesium.Numerous potential drug interactions; consult a reputable drug interaction checker or resource.Avoid in combination with nephrotoxic drugs. | Caution is advised in patients with established or at high-risk of osteoporosis (e.g., postmenopausal, chronic systemic corticosteroid therapy). Ensure adequate calcium and vitamin D intake.‚Äã[45]‚Äã[46]Cobicistat has no antiviral activity but is a CYP3A inhibitor used to boost elvitegravir levels.Renal impairment: do not use if pretreatment ClCr <70 mL/min. Cobicistat, elvitegravir and emtricitabine are not available as single-entity products. |
| **emtricitabine** (Descovy) | 200 mg/25 mg once daily with or without foodIn combination with a boosted PI: 200 mg/10 mg once daily with or without food | Renal toxicity; monitor renal function, urinalysis and serum phosphorus.Lactic acidosis and hepatotoxicity have been reported.Decreased BMD and increased osteoporotic fractures. TAF has potentially less loss of BMD and renal function compared with TDF.‚Äã[55]‚Äã[56] | Numerous potential drug interactions; consult a reputable drug interaction checker or resource.TAF should not be used with rifamycin. | Renal impairment (ClCr <30 mL/min): not recommended. Emtricitabine and TAF are not available as single-entity products. |
| **emtricitabine** (Truvada, generics) | 200 mg/300 mg once daily PO with or without food | Renal toxicity; monitor renal function, urinalysis and serum phosphorus.Lactic acidosis and hepatotoxicity have been reported.Decreased BMD and increased osteoporotic fractures. | Numerous potential drug interactions; consult a reputable drug interaction checker or resource.Avoid in combination with nephrotoxic drugs. | Caution is advised in patients with established or at high-risk of osteoporosis (e.g., postmenopausal, chronic systemic corticosteroid therapy). Ensure adequate calcium and vitamin D intake.‚Äã[45]‚Äã[46]Renal impairment (ClCr <30 mL/min): not recommended. Emtricitabine is not available as a single-entity product. |
| **emtricitabine** (Odefsey) | 200 mg/25 mg/25 mg once daily PO with food | Depression, insomnia, rash, headache.Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable).QTc interval prolongation.Renal toxicity; monitor renal function, urinalysis and serum phosphorus.Lactic acidosis and hepatotoxicity have been reported.Decreased BMD and increased osteoporotic fractures. TAF has potentially less loss of BMD and renal function compared with TDF.‚Äã[55]‚Äã[56] | RPV absorption is acid dependent; stagger administration of antacids (2 h before or 4 h after RPV) or H2-receptor antagonists (12 h before or 4 h after RPV). Use with PPIs is contraindicated.TAF should not be used with rifamycin. | Not recommended to start if HIV RNA <100 000 copies/mL or CD4 count <200 cells/mcL.Renal impairment (ClCr <30 mL/min): not recommended. Emtricitabine and TAF are not available as a single-entity product. |
| **emtricitabine** (Complera) | 200 mg/25 mg/300 mg once daily PO with food (‚â•390 kCal) | Depression, insomnia, rash, headache.Early benign increase in serum creatinine (first 2‚Äì4 wk, then stable).QTc interval prolongation.Renal toxicity; monitor renal function, urinalysis and serum phosphorus.Lactic acidosis and hepatotoxicity have been reported.Decreased BMD and increased osteoporotic fractures. | RPV absorption is acid dependent; stagger administration of antacids (2 h before or 4 h after RPV) or H2-receptor antagonists (12 h before or 4 h after RPV). Use with PPIs is contraindicated.Numerous potential drug interactions; consult a reputable drug interaction checker or resource.Avoid in combination with nephrotoxic drugs. | Not recommended to start if HIV RNA <100 000 copies/mL or CD4 count <200 cells/mcL.Caution is advised in patients with established or at high-risk of osteoporosis (e.g., postmenopausal, chronic systemic corticosteroid therapy). Ensure adequate calcium and vitamin D intake.‚Äã[45]‚Äã[46]Renal impairment (ClCr <50 mL/min): not recommended. Emtricitabine is not available as a single-entity product. |
| **lamivudine** (Combivir, generics) | 150 mg/300 mg BID PO with or without food | Nausea, headache, malaise, fatigue, rash, myositis, myocarditis, anemia, leukopenia, hepatic steatosis, elevated liver enzymes, lactic acid and CK. Long-term use associated with peripheral lipoatrophy. | Lamivudine has a low potential for drug interactions.Additive hemotoxicity with other agents, e.g., anemia with dapsone, foscarnet, ganciclovir, pentamidine, ribavirin.Numerous potential drug interactions; consult a reputable drug interaction checker or resource. | Renal impairment (ClCr <30 mL/min): not recommended. Use individual products and adjust each agent accordingly. |


**ü´ò Renal Monitoring - Monitor kidney function when using this medication**

<!-- AI_IMAGE_PLACEHOLDER: images/kidney.gif -->

bone mineral density

chemokine receptor 5

creatine kinase

creatinine clearance

central nervous system

chemokine receptor type 4

cytochrome P450

efavirenz

gastrointestinal

human immunodeficiency virus

non-nucleoside reverse transcriptase inhibitor

nucleoside reverse transcriptase inhibitor

nevirapine

protease inhibitor

pharmacokinetic

proton pump inhibitor

ribonucleic acid

rilpivirine

ritonavir

tenofovir alafenamide

tenofovir disoproxil fumarate

#### Suggested Readings

British Columbia Centre for Excellence in HIV/AIDS. (Revised August 2021). *Primary care guidelines for the management of HIV/AIDS in Adults in British Columbia* [PDF file]. Available from: https://bccfe.ca/therapeutic-guidelines/primary-care-guidelines.

Cohen MS, Chen YQ, McCauley M et al. Antiretroviral therapy for the prevention of HIV-1 transmission. *N Engl J Med* 2016;375(9):830-9.

Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 with early antiretroviral therapy. *N Engl J Med* 2011;365(6):493-505.

DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. (September 21, 2022).* Guidelines for the use of antiretroviral agents in adults and adolescents with HIV* [PDF file]. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf.

LeMessurier J,¬†Traversy G,¬†Varsaneux O et al. Risk of¬†sexual¬†transmission¬†of¬†human immunodeficiency virus¬†with¬†antiretroviral¬†therapy,¬†suppressed¬†viral load¬†and¬†condom¬†use: a¬†systematic review. *CMAJ*¬†2018;190(46):E1350-E1360.

Loutfy M, Kennedy VL, Poliquin V et al. No. 354-Canadian HIV pregnancy planning guidelines. *J Obstet Gynaecol Can* 2018;40(1):94-114.

Mbuagbaw L, Hajizadeh A, Wang A et al. Overview of systematic reviews on strategies to improve treatment initiation, adherence to antiretroviral therapy and retention in care for people living with HIV: part 1. *BMJ Open* 2020;10(9):e034793.

Montaner JS, Lima VD, Harrigan PR et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality, and HIV transmission: the ‚ÄúHIV Treatment as Prevention‚Äù experience in a Canadian setting. *PloS One* 2014;9(2):e87872.

Saag MS, Gandhi RT, Hoy JF et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel. *JAMA* 2020;324(16):1651-69.

Samji H, Cescon A, Hogg RS et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. *PLoS One* 2013;8(12):e81355.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J et al. CD4+ count-guided interruption of antiretroviral treatment. *N Engl J Med* 2006;355(22):2283-96.

Thompson MA, Horberg MA, Agwu A et al. Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis* 2021;73(11):e3572-e3605.

Thompson MA, Mugavero MJ, Amico KR et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care Panel. *Ann Intern Med* 2012;156(11):817-33.

#### References


---

## Source Information

**Original Source:** [https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/hiv_infection](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/hiv_infection)  
**Content Type:** therapeutic_choices  
**Processed:** 2025-05-29 07:19 UTC  
**Source System:** Canadian Pharmacists Association (CPS)

### How to Cite
> Canadian Pharmacists Association. *hiv_infection*. 
> CPS Online. Retrieved 2025-05-29 07:19 UTC from https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/hiv_infection


```

*Note: This document was processed using automated tools. Always refer to the original source for the most up-to-date information.*

---
*Document processed with CPS Pipeline v1.0 ‚Ä¢ [Source URL](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/hiv_infection)*
